SEC Comment Letter for Chemomab Therapeutics Ltd. (CMMB) (CIK 0001534248) (CMMB) — May 5, 2021
Chemomab Therapeutics Ltd. (CMMB) (CIK 0001534248)
Date: May 5, 2021 · CIK: 0001534248 · Accession: 0000000000-21-005731
AI Filing Summary & Sentiment
File numbers found in text: 333-255658
Letter
United States securities and exchange commission logo May 5, 2021 Adi Mor Chief Executive Officer Chemomab Therapeutics Ltd. Kiryat Atidim, Building 7 Tel Aviv, Israel 6158002 Re:Chemomab Therapeutics Ltd. Registration Statement on Form S-3 Filed April 30, 2021 File No. 333-255658 Dear Dr. Mor: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jane Park at 202-551-7439 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: David Glatt, Esq.
Show Raw Text
United States securities and exchange commission logo
May 5, 2021
Adi Mor
Chief Executive Officer
Chemomab Therapeutics Ltd.
Kiryat Atidim, Building 7
Tel Aviv, Israel 6158002
Re:Chemomab Therapeutics Ltd.
Registration Statement on Form S-3
Filed April 30, 2021
File No. 333-255658
Dear Dr. Mor:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jane Park at 202-551-7439 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: David Glatt, Esq.